Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors: Results of an update conference based on evidence-based medicine (EBM);Interdisziplinarer konsensus zur diagnostik und therapie von hodentumoren: Ergebnisse einer update-konferenz auf grundlage evidenzbasierter medizin (EBM)

Strahlentherapie und Onkologie

Volumn 176, Issue 9, 2000, Pages 388-405

  Souchon, Rainer ^a   Krege, Susanne ^b   Schmoll, Hans Joachim ^c   Albers, Peter ^d   Beyer, Jörg ^e   Bokemeyer, Carsten ^f   Claßen, Johannes ^f   Dieckmann, Klaus Peter ^g   Hartmann, Michael ^h   Heidenreich, Axel ^e   Höltl, Wolfgang ⁱ   Kliesch, Sabine ^j   Köhrmann, Kai Uwe ^k   Kuczyk, Markus ^l   Schmidberger, Heinz ^m   Weinknecht, Stephan ⁿ   Winter, Eva ^k   Wittekind, Christian ^o   Bamberg, Michael ^f  

^a Arbeitsgemeinschaft Radiologische Onkologie (ARO)   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g ALBERTINEN KRANKENHAUS   (Germany)

^h Bundeswehrkrankenhaus Hamburg   (Germany)

ⁱ KAISER FRANZ JOSEF HOSPITAL   (Austria)

^j UNIVERSITY OF MÜNSTER   (Germany)

^k Urologische Klinik   (Germany)

^l HANNOVER MEDICAL SCHOOL   (Germany)

^m UNIVERSITY OF GÖTTINGEN   (Germany)

ⁿ Urologischen Abteilung   (Germany)

^o UNIVERSITY OF LEIPZIG   (Germany)

more..

Author keywords

Evidence based medicine (EBM); Interdisciplinary diagnostic and treatment strategies; Testicular germ cell tumors

Indexed keywords

CANCER RADIOTHERAPY; EVIDENCE BASED MEDICINE; GERM CELL TUMOR; HUMAN; MALE; MALE GENITAL TRACT TUMOR; MULTIMODALITY CANCER THERAPY; PROGNOSIS; REVIEW; SEMINOMA; TESTIS TUMOR; CANCER STAGING; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; NEOPLASM; PATHOLOGY; PATIENT CARE;

EVIDENCE-BASED MEDICINE; HUMANS; MALE; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; PATIENT CARE TEAM; PROGNOSIS; TESTICULAR NEOPLASMS;

EID: 0034265129     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00002347     Document Type: Review

References (264)

1. Interdisziplinare Konsensus-Konferenz zur 'Diagnostik und Therapie von Hodentumoren'
2. Interdisziplinare Konsensus-Konferenz zur Diagnostik und Therapie von Hodentumoren
3. Deutsche Krebsgesellschaft e.V. Qualitatssicherung in der Onkologie
4. Practice guidelines, a new reality in medicine II. Methods of developing guidelines
5. Checkliste 'Methodische Qualitat von Leitlinien' auf der Grundlage der 'Beurteilungskriterien fur Leitlinien der Bundesarztekammer und der Kassenarztlichen Bundesvereinigung'
6. Die Cochrane Collaboration
7. Leitlinien und Evidenz-basierte Medizin in Deutschland
8. Prevalence of bilateral testicular germ cell tumors and early detection based on contralateral testicular intraepithelial neoplasia
9. Ergebnisse einer engmaschigen Hodentumornachsorge
10. Risk of bilateral testicular germ cell tumors in Denmark: 1960 - 1984
11. Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: Study of 27 cases in 500 patients
12. Testicular cancer, cryptorchidism, inguinal hernia, testicular atrophy and genital malformations: Case-control studies in Denmark
13. Birth order and risk of testicular cancer
14. Familial testicular cancer and urogenital developmental anomalies
15. Occurrence of testicular cancer in patients operated on for cryptorchidism and inguinal hernia
16. Risk factor for testicular cancer: A case control study in twins
17. The prevalence of familial testicular cancer
18. Familial testicular cancer: A report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis
19. Klinische und biologische Charakteristika familiarer, bilateraler und sporadischer Keimzelltumoren des Hodens
20. Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population based study
21. Testicular cancer
22. Diagnostik und Therapie von Hodentumoren
23. Extragonadal germ cell tumour: A clinical study
24. 'Burned out' testicular tumour: A rare form of germ cell neoplasias
25. Alpha-foetoprotein heterogeneity: What is its value in managing patients with germ cell tumours?
26. Treatment and outcome of patients with extragonadal germ cell tumours - The Norwegian Radium Hospital's experience 1979-94
27. Elevated human chorionic gonadotropin concentrations in the testicular vein and in peripheral venous blood in seminome patients. An analysis of various parameters
28. Primary retroperitoneal extragonadal germ cell tumour
29. Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors
30. Orchiectomy after chemotherapy in patients with metastatic testicular cancer
31. A review of scrotal violation in testicular cancer: Is adjuvant local therapy necessary?
32. Does delayed diagnosis or scrotal incision affect outcome for men with nonseminomatous germ cell tumors?
33. The clinical implications of procedural deviations during orchiectomy for nonseminomatous testis cancer
34. Ist eine schnellschnittgesteuerte Therapieplanung bei testikularen Raumforderungen sinnvoll?
35. Radical orchiectomy and benign testicular conditions
36. Accuracy of frozen section examination of testicular tumors
37. A conservative approach to bilateral testicular germ cell tumors
38. Testis-preserving surgery in bilateral testicular germ cell tumours
39. Organ preserving surgery of malignant germ cell tumors
40. Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms
41. Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: Defining a high risk group
42. Placental-alkaline phosphatase as a marker of carcinoma-in-situ of the testis. Comparison with monoclonal antibodies M2A and 43-9F
43. Immunohistochemical expression of embryonal marker TRA-1-60 in carcinoma in situ and germ cell tumors of the testis
44. Methodik diagnostischer Validierungsstudien
45. Empirical evidence of design-related bias in studies of diagnostic tests
46. Early stage and advanced seminoma: Role of radiation therapy, surgery, and chemotherapy
47. Lymphknotenstaging maligner testikularer Keimzelltumoren
48. A rational approach to managing stage I nonseminomatous germ cell cancer
49. Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: A combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment
50. The role of computed tomographic examination of the pelvis in the management of testicular germ cell tumours
51. Imaging of the thorax in the management of germ cell testicular tumours
52. Leitlinien der Bundesarztekammer zur Qualitatssicherung in der Computertomographie
53. Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors
54. Prognostic factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis
55. Chest staging in testis cancer patients: Imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results
56. Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell tumor using size criteria of retroperitoneal lymph nodes
57. Testicular Cancer Intergroup Study: Staging relationships and outcome in early stage testicular cancer: A report from the Testicular Cancer Intergroup Study
58. Hodentumoren
59. Quantifizierung der Lymphknotenperfusion mittels farbkodierter Duplexsonographie
60. Lymph node metastases: Safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - Initial clinical experience
61. Magnetic resonance imaging of retroperitoneal lymph node metastases of non-seminomatous germ cell tumors of the testis
62. Becken
63. Positron emission tomography in the clinical staging of patients with stage I and II germ cell tumors
64. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? - Results of a study of 50 patients
65. Germ cell tumor (GCT): Staging and therapy control with (18)FDG-PET. First results of German multicenter trial
66. Positron emissions tomography in urological oncology
67. Die Positronenemissionstomographie mit (18F)-2-fluoro-2-deoxy-D-glukose (18FDG-PET) bei der Diagnostik retroperitonealer Lymphknotenmetastasen von Hodentumoren
68. Positronen-Emissions-Tomographie in der Onkologie
69. Klinische Wertigkeit der Positronen-Emissions-Tomographie (PET) bei onkologischen Fragestellungen: Ergebnisse einer interdisziplinaren Konsensuskonferenz
70. Relevance of positron emission tomography (PET) in oncology
71. Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: Prospects for detection and management
72. The International Germ Cell Consensus Classification: A prognostic factor based staging system for metastatic germ cell cancer
73. Treatment of brain metastases in patients with testicular cancer
74. Treatment outcome of patients with brain metastases from malignant germ cell tumors
75. Maligne Keimzelltumoren des Mannes
76. International consensus prognostic classification for metastatic germ cell tumours treated with platinum based chemotherapy: Final report of the International Germ Cell Cancer Collaborative Group (IGCCCG)
77. Health-related quality of life in patients treated for testicular cancer
78. Cryopreservation of semen from adolescent patients with malignancies
79. Cryopreservation of sperm
80. Gonadal function in men with testicular cancer: Biological and clinical aspects
81. Paternity in a patient with testicular seminoma and contralateral testicular intraepithelial neoplasia
82. Semen quality in testicular tumour and CIS in the contralateral testis
83. Current concepts of radiation treatment of carcinoma in situ of the testis
84. Paternity in patients with bilateral testicular germ cell tumors
85. Semen parameters and testicular pathology in men with testicular cancer and contralateral carcinoma in situ or bilateral testicular malignancies
86. Therapie mit Testosteron
87. Pharmacology and clinical use of testosterone
88. Prognostic factors for relapse in stage I seminoma managed by surveillance
89. Prognostic factors for relapse in stage I testicular seminoma treated with surveillance
90. Prognostic factors in seminomas with special respect to HCG: Results of a prospective multicenter study
91. Surveillance following orchiectomy for stage I testicular seminoma
92. Longterm results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors
93. Risk-adapted treatment of clinical stage I non-seminoma testis cancer
94. Risk adapted management for NSGCT stage 1 - Long-term results of a multicenter study
95. Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: Rationale for different risk-adapted treatment
96. Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: A prospective trial
97. Tumor proliferative activity is predictive of pathological stage in clinical stage A non-seminomatous testicular germ cell tumors
98. Risk-related adjuvant chemotherapy for stage I non-seminoma of the testis
99. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party
100. Clinical stage I testis cancer: Long-term outcome of patients on surveillance
101. MIB-1 immunohistochemistry predicts patients at low risk of metastasis in clinical stage I non-seminomatous testicular germ cell tumors
102. Percentage of embryonal carcinoma and vascular invasion predict pathologic stage in clinical stage 1 non-seminomatous testicular cancer
103. Predictive parameters of biologic behavior of early stage nonseminomatous testicular germ cell tumors
104. Immunohistochemical expression of Ki-67 to predict lymph node involvement in clincial stage I nonseminomatous germ cell tumors
105. A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: A 10-year follow up
106. Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma-predominant testis cancer
107. Predictors of recurrent clinical stage I nonseminomatous testicular cancer. A prospective clinicopathologic study
108. Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: A report from the Testicular Cancer Intergroup Study
109. Prognosefaktoren bei metastasierten seminomatosen und nichtscminomatosen Hodentumoren
110. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours
111. Carcinoma in situ of the undescended testis
112. Low-dose radiation therapy for testicular intraepithelial neoplasia
113. The value of the biopsy of the contralateral testis in patients with testicular germ cell cancer: The recent German experience
114. Effect of chemotherapy on carcinoma in situ of the testis
115. Prognostic factors for relapse following surveillance in seminoma stage I patients
116. Results of a policy of surveillance in stage I testicular seminoma
117. Stage I testicular seminoma: Results of adjuvant irradiation and surveillance
118. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial
119. Radiotherapy for stage I, IIA/B testicular seminoma
120. Is pelvic RT necessary in the treatment of stage I testicular seminoma?
121. Omission of the pelvic irradiation in stage I testicular seminoma: A study of postorchiectomy paraaortic radiotherapy
122. Surveillance for stage I testicular seminoma. Is it a good option?
123. Short fractionation para-aortic radiotherapy for stage I seminoma of the testis
124. Adjuvant treatment of clinical stage I seminoma: Is one single course of carboplatin sufficient?
125. Treatment of stage I seminoma: More choice, more dilemmas
126. Seventeen years experience of phase I/II studies of single agent platinum compounds as alternatives to radiation for metastatic and stage I seminoma
127. Phase II study: Adjuvant single-agent carboplatin therapy for clinical stage I seminoma
128. Postorchiectomy radiotherapy for stages I and II testicular seminoma
129. Management of stage I seminoma: Radiotherapy
130. Risk of second malignant neoplasms among long-term survivors of testicular cancer
131. Risk of leukemia following radiotherapy and chemotherapy for testicular cancer
132. The management of stage I testis cancer
133. Surveillance following orchiectomy for stage I seminoma of the testis
134. Patients' and doctors' perception of long-term morbidity in patients with testicular cancer clinical stage I
135. Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: A prospective multicenter study
136. Postoperative radiotherapy for stage I/II seminoma: Results of 212 patients
137. Orchidectomy followed by radiotherapy in 176 stage I and II testicular seminoma patients: Benefits of a 10-year follow-up study
138. Results of radiotherapy for 230 patients with stage I-II seminomas
139. Results of treatment in irradiated testicular seminoma patients
140. Radiation therapy for stage I and IIA testicular seminoma
141. Radiation therapy of seminoma: 17-year experience at the Joint Center for radiation therapy
142. Radiotherapy for stage I and II testicular seminoma: Results and morbidity in 238 patients
143. Management of stage II seminoma
144. Long-term evaluation of postorchiectomy radiotherapy for stage II seminoma
145. The significance of scrotal interference in stage I testicular cancer managed by orchiectomy and surveillance
146. Seminoma of the testis: Results of treatment and patterns of failure after radiation therapy
147. The role of radiation in stage II testicular seminoma
148. Comparison between clinical and pathological staging in low stage nonseminomatous germ cell testicular tumors
149. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965-1989): Modifications of technique and impact on ejaculation
150. Optimizing follow up for early stage nonseminomatous testicular cancer
151. Surgical treatment of stage-I non-seminomatous germ cell testis tumor
152. Nervesparing retroperitoneal lymphadenectomy with preservation of ejaculation
153. Complications of primary retroperitoneal lymph node dissection
154. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: Long-term results of a prospective trial
155. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: A Medical Research Council report
156. Long term effects on sexual function and fertility after treatment of testicular cancer
157. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer
158. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment
159. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: The Indiana University experience (1965 to 1989)
160. Adjuvant chemotherapy for stage II nonseminomatous germ cell cancer of the testis
161. Comparison of the natural history of stage I nonseminoma and seminoma testis using the results of expectant management
162. Nerve-sparing retroperitoneal lymphadenectomy for low stage testicular cancer
163. Fertility after chemotherapy for testicular germ cell cancer
164. Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer
165. No adjuvant chemotherapy in selected patients with pathological stage II nonseminomatous germ cell tumors of the testis
166. Adjuvant chemotherapy of metastatic stage II non-seminomatous testis tumor
167. Management of the post-chemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumors (GCT)
168. Initial chemotherapy for stage II testicular nonseminoma
169. Markers and management of germ-cell tumours of the testis
170. Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: A preliminary report
171. Clinical stage II non-seminatous germ cell testicular tumors. Results of management by primary chemotherapy
172. Long term somatic side-effects and morbidity in testicular cancer patients
173. Active surveillance after orchiectomy for nonseminomatous testicular germ cell tumors: Late relapse may occur
174. Long-term toxicity of chemotherapy for testicular cancer-the cost of cure
175. Secondary neoplasms following treatment of malignant germ cell tumors
176. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group
177. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial
178. Hematopoetic growth factors and treatment of testicular cancer: Biological interactions, routine use and dose intensive chemotherapy
179. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom
180. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular nonseminoma: A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer
181. Management of intermediate-prognosis germ-cell cancer: Results of a phase I/II study of Taxol-BEP
182. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study
183. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis
184. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors
185. Brain metastases and testicular tumors: Long-term survival
186. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease
187. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy
188. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance
189. Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels
190. Treatment of advanced metastatic seminoma: Experience in 55 cases
191. Residual mass after chemotherapy for seminoma: Changing concepts of management
192. Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection
193. Value of retroperitoneal lymph node dissection in advanced testicular seminoma
194. Chemotherapy of metastatic seminoma: The Southeastern Cancer Study Group experience
195. Residual mass: An indication for further therapy in patients with advanced seminoma following systemic chemotherapy
196. Advanced seminoma treatment with cisplatinum based combination chemotherapy or carboplatin (JM8)
197. Radiotherapy after chemotherapy for metastatic seminoma - A diminishing role
198. Stellenwert der Strahlentherapie von Residualtumoren nach Chemotherapie metastasierter Seminome
199. Management of residual mass in advanced seminoma: Results and recommendations from Memorial Sloan-Kettering Cancer Center
200. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer
201. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: Recommendations for patient selection
202. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer
203. The surgical management of advanced abdominal disease
204. Detection of retroperitoneal metastases in early-stage nonseminomatous testicular cancer: Analysis of different CT criteria
205. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors
206. Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer?
207. Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumors: Prognostic value and therapeutic benefit
208. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors
209. Complications of post-chemotherapy retroperitoneal lymph node dissection
210. Postchemotherapy resections of residual masses from metastatic non-seminomatous germ cell tumors
211. Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: Is a modified dissection and resection of the residual mass sufficient?
212. Postchemotherapeutic surgery for metastatic testicular germ cell tumors: Results of extended primary chemotherapy and limited surgery
213. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: Multivariate analysis of individual patient data from six study groups
214. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours
215. Postchemotherapy residual masses in germ cell tumor patients: Content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party
216. Bei welchen markerpositiven Patienten mit Keimzelltumoren ist die Residualtumorresektion sinnvoll?
217. Thoracic metastasectomy for germ cell tumours: Long term survival and prognostic factors
218. Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors
219. The case for retroperitoneal lymphadenectomy after chemotherapy for selected patients with nonseminomatous tumours of the testis
220. The role of surgery in the combined management of metastases from malignant teratomas of the testis
221. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma
222. Salvagetherapie rezidivierter und refraktarer Hodentumoren
223. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor
224. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor prognosis metastatic germ cell tumor: A randomized Medical Research Council/European Organization for Research and Treatment of Cancer study
225. High-dose versus conventional-dose first-salvage treatment in nonseminoma: A matched-pair analysis
226. Late relapse of testicular cancer
227. The changing role of surgery in metastatic non-seminomatous germ cell tumour
228. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone
229. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy
230. Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy?
231. Late relapse of germ cell tumors after cisplatin-based chemotherapy
232. Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumors remaining marker positive after inductive chemotherapy
233. Surgical salvage of chemorefractory germ cell tumors
234. Treatment of recurrent germ cell tumors
235. Surgery as salvage therapy in chemotherapy-resistant nonseminomatous germ cell tumors
236. Hodentumoren - Todesfalle und Rezidive nach inadaquater Therapie
237. Impact of the treating institution on survival of patients with 'poor-prognosis' metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborativ Group and the Medical Research Council Testicular Cancer Working Party
238. Testicular cancer - Who needs surveillance pelvic CT?
239. Die risikogesteuerte Hodentumornachsorge
240. What is the appropriate follow up after treatment?
241. Empfehlungen der ACS (American Cancer Society) Consultants
242. The management and clinical course of testicular seminoma: 15 years' experience at a single institution
243. Long-term results of adjuvant irradiation or surveillance in stage I testicular seminoma
244. Management of seminoma of the testis: Recommandations based on treatment results
245. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: A single center 10-years experience
246. Progression detection of stage I nonseminomatous testis cancer on surveillance: Implications for the follow-up protocol
247. An analysis of surveillance for stage I combined teratoma-seminoma of the testis
248. Clinical stage B nonseminomatous germ cell testis cancer: The Indiana University experience (1965-1985) using routine primary retroperitoneal lymph node dissection
249. Stage II seminomatous testis cancer: The roles of primary and adjuvant chemotherapy
250. Adjuvant chemotherapy for stage II nonseminomatous testicular cancer: What is 1st role?
251. Evaluation of primary standard cisplatin-based chemotherapy for clinical stage II non-seminomatous germ cell tumours of the testis
252. Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis
253. Initial chemotherapy for stage II testicular nonseminoma
254. Biology of metastases and its clinical implications: Testicular germ-cell tumors
255. A single-center observational study of surgery and late malignant events after chemotherapy for germ cell cancer
256. How long to follow up patients with testicular germ cell tumours?
257. Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors